References
- Aithal, G. P., Day, C. P., Kesteven, P. J. L., and Daly, A. K., Association of polymorphism in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 353, 717-719 (1999) https://doi.org/10.1016/S0140-6736(98)04474-2
- Furuya, H, Fernandez-Salguero, P., Gregory, W., Taber, H., Steward, A., Gonzalez, F., and Idle, J. R., Genetic polymorphism of CYP2C9 and its effects on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics, 5, 389-392 (1995) https://doi.org/10.1097/00008571-199512000-00008
- Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., and Ansell, J., et al., Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest,114, 445S-469S (1998) https://doi.org/10.1378/chest.114.5_Supplement.445S
- James, A. H., Britt, R. P., Risking, C. L., and Thompson, S. G., Factors affecting the maintenance dose of warfarin. J. Clin. Pathol., 45, 704-706 (1992) https://doi.org/10.1136/jcp.45.8.704
- Kaminsky, L. S. and Zhang, Z.-Y., Human p450 metabolism of warfarin. Pharmacol. Ther., 73, 67-74 (1997) https://doi.org/10.1016/S0163-7258(96)00140-4
- Kimura, M., Ieiri, I., Mamiya, K., Urae, A., and Higuchi, S., Genetic polymorphism of cytochrome P450s, CYP2C19 and CYP in a Japanese population. Ther. Drug. Monit., 20, 243-247 (1998) https://doi.org/10.1097/00007691-199806000-00001
- Landefeld, C. S. and Beyth, R. J., Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am. J. Med., 95, 315-328 (1993) https://doi.org/10.1016/0002-9343(93)90285-W
- Miners, J. O. and Birkett, D. J., Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol., 45, 277-280 (1998) https://doi.org/10.1046/j.1365-2125.1998.00674.x
- Nasu, K., Kubota, T., and Ishizaki, T., Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics, 7, 405-409 (1997) https://doi.org/10.1097/00008571-199710000-00011
- Redman, A. R., Implications of cytochrome P4502C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy, 21, 235-242 (2001) https://doi.org/10.1592/phco.21.2.235.34106
- Rettie, A. E., Wienkers, L. C., Gonzalez, F. J., Trager, W. F., and Korzekwa, K. R., Impaired S-warfarin metabolism catalyzed by R144C allelic variant of CYP2C9. Pharmacogenetics, 4, 39-42 (1994) https://doi.org/10.1097/00008571-199402000-00005
- Stubbins, M. J., Harries, L. W., Smith, G., Tarbit, M. H., and Wolf, C. R., Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics, 6, 429-439 (1996) https://doi.org/10.1097/00008571-199610000-00007
- Sullivan-Klose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z.-Y., Kaminsky, L. S., and Shenfield, G. M., et al., The role of the CYP2C9-Leu359 allelic variant in the tolbutamice polymorphism. Pharmacogentics, 6, 341-349 (1996) https://doi.org/10.1097/00008571-199608000-00007
- Takahashi, H., Kashima, T., Momizo, Y., Muramoto, N., Shimizu, T., and Nasu, K., et al., Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol. Ther., 63, 519-528 (1998) https://doi.org/10.1016/S0009-9236(98)90103-5
- Wang, S. L., Huang, J.-D., Lai, M. D., and Tsai, J. J., Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics, 5, 37-42 (1995) https://doi.org/10.1097/00008571-199502000-00004
- Yoon, Y. R., Shon, J. H., Kim, M. K., Lim, Y. C., Lee, H. R., Park, J. Y., Cha, I. J., and Shin, J. G., Frequency of cytochorome P450 2C9 mutant alleles in a Korean population. Br. J. Clin. Pharmacol., 51, 277-280 (2001) https://doi.org/10.1046/j.1365-2125.2001.00340.x